These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29272564)

  • 1. Mechanisms of Action and Clinical Development of Elotuzumab.
    Ritchie D; Colonna M
    Clin Transl Sci; 2018 May; 11(3):261-266. PubMed ID: 29272564
    [No Abstract]   [Full Text] [Related]  

  • 2. Elotuzumab: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
    Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
    Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
    Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
    Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab May Slow Multiple Myeloma.
    Cancer Discov; 2015 Jul; 5(7):OF10. PubMed ID: 25998398
    [No Abstract]   [Full Text] [Related]  

  • 9. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CS1-directed monoclonal antibody therapy for multiple myeloma.
    Benson DM; Byrd JC
    J Clin Oncol; 2012 Jun; 30(16):2013-5. PubMed ID: 22547601
    [No Abstract]   [Full Text] [Related]  

  • 13. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
    Grosicki S; Barchnicka A
    Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
    Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
    N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
    Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
    Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elotuzumab for the treatment of multiple myeloma.
    Moreau P; Touzeau C
    Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elotuzumab in multiple myeloma.
    Burki TK
    Lancet Oncol; 2018 Dec; 19(12):e675. PubMed ID: 30449660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.